Publication
Repurposing the third-generation EGFR inhibitor osimertinib to synergize with paclitaxel and extend survival in anaplastic thyroid cancer.
Ran Jie, Xiawei Shen
Immunopharmacology and immunotoxicologySep 22, 2026PMID 42773810doi:10.1080/08923973.2026.2735423 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Anaplastic thyroid cancer (ATC) is a highly aggressive malignancy with limited therapeutic options and poor prognosis. This study aimed to identify effective targeted agents and evaluate their therapeutic potential in combination with paclitaxel. METHODS: High-throughput drug…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Thyroid Gland Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.